CITA-Alzheimer's Foundation

If you are the contact person for this centre and you wish to make any changes, please contact us.

Contact
SMC participants
Pablo Martínez-Lage Álvarez

 Neurologist, scientific director of the CITA-Alzheimer's Foundation
 

Contents related to this centre
EMA
Alzheimer's
EMA revises earlier decision and decides to approve lecanemab for Alzheimer's disease

Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks.